BioNTech's Vision and Strategy - BioNTech aims to build a global immunotherapy powerhouse translating science into survival[13] - BioNTech has distributed 5 billion doses of COVID-19 vaccine globally[12] - BioNTech is leveraging AI to pioneer personalized immunotherapies[62] InstaDeep's AI Capabilities and Technologies - InstaDeep's AI supercomputer, Kyber, has ~500 PetaFLOPS of Nvidia H100 GPUs and 86,000 CPU Cores[105] - InstaDeep's AI training platform, AIChor, has seen +15,000 experiments per month in 2025 with +75% GPU usage[109] - Nucleotide Transformer (NTv3) pre-trained on genomes from >150,000 species and post-trained on >17,000 functional tracks across 16 species[154] AI-Driven Innovation in Genomics and Proteomics - InstaNovo V2 achieves up to 2x the number of identifications in peptide sequencing[263] - AI-assisted tissue annotation tool increased pathologist efficiency fivefold (5x)[265] - AI pipeline achieves an average 50,000-fold TCR binding enhancement increase over WT[345]

Core Insights - BriaCell Therapeutics Corp. has announced that its personalized immunotherapy Bria-OTS has successfully cleared safety evaluations in a Phase 1/2 study and has begun dosing patients in combination with a checkpoint inhibitor for metastatic breast cancer [1][6] Company Developments - Bria-OTS is a next-generation version of Bria-IMT™, currently in a pivotal Phase 3 trial, aimed at enhancing immune responses against tumors [2] - The transition to the checkpoint inhibitor combination cohort follows a successful three-patient monotherapy safety run-in, with the first monotherapy patient showing complete resolution of lung metastasis [2][6] - The ongoing study will evaluate Bria-OTS in combination with a checkpoint inhibitor in up to 12 patients, focusing on safety and objective response rate (ORR) as primary endpoints [3][6] Future Plans - BriaCell plans to further assess Bria-OTS+™, an optimized version of the platform, across multiple cancer types, including breast and prostate cancers [3]